Redondo MJ, et al. - In the present study, the researchers examined the ability of a type 1 diabetes (T1D) genetic risk score (GRS) to forecast progression of islet autoimmunity and T1D in at-risk individuals. For this investigation, the 1,244 TrialNet Pathway to Prevention study participants who were genotyped with Illumina ImmunoChip were studied. Out of 953 members with multiple positive autoantibodies at screening, 419 developed diabetes. Results revealed that higher GRS was significantly correlated with increased progression rate from single to multiple positive autoantibodies after adjusting for age, autoantibody type, ethnicity, and sex. The findings demonstrated that the T1D GRS independently predicts progression to T1D and improves prophecy along T1D stages in autoantibody-positive relatives.